Idiopathic pulmonary fibrosis (IPF) is a condition in which the tissues deep inside the lungs become thick and stiff, or even scarred overtime. This formation of scarred tissue is termed as fibrosis this leads to extreme difficulty in breathing. When the lung tissue thickens, it cannot move oxygen into the blood stream, and this leads to lack of oxygen to the brain and other body organs. Idiopathic pulmonary fibrosis is a chronic and eventually fatal disease which is characterized by a gradual decline in lung function. The term pulmonary fibrosis would mean extreme scarring of the lung tissue and leading to worsening of dyspnea, and fibrosis is generally linked with lack of prognosis. It is not completely ascertained whether what causes such a condition (hence the name idiopathic), however, it broadly affects elderly people who are around 70 to 75 years of age and is quite rare in an individual under 50. Various treatments aid in lessening the worseness rate of IPF, nevertheless there is presently no justified treatment which can arrest or reverse the scarring of lungs.This disease varies from person to person, where in a few people the fibrosis happens in a rapid manner, while in other the process is quite slow. It has been observed that people, who suffer from pulmonary fibrosis, live only approximately three to five years post diagnosis and the most common cause of death associated with IPF is respiratory failure. Some of the other cases include heartfailure, pulmonary embolism, pulmonary hypertension, lung cancer, and pneumonia.
A recent survey on idiopathic pulmonary fibrosis market states that genetic factor might play a significant role in causing IPF, and if more than one member in the family has IPF, then the disease is known a familial IPF. A few symptoms of idiopathic pulmonary fibrosis are shortness of breath, tiredness, constant fry cough, sudden weight loss; swollen finger tips (clubbed fingers). The diagnosis of IPF needs exclusion of other known causes of ILDs and the existence of a typical radiological pattern which is determined through high resolution computed tomography (HRCT). Extensive R&D measures have helped doctors learn more about IPF, which has led to early diagnosis of this disease. Besides, researchers are examining various medicines which might slow down the overall progress. These efforts might have bettered the lifespan and quality of life for individuals who have the disease.